PPD
PPD is recorded as a service provider in 1,302 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 1,302 trials · Latest update first
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
Sponsor Astrazeneca AB
- Start (EU)
- Latest update
- Estimated end
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
Sponsor DICE Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study used 46 sites across Canada (10), Czechia (3), Germany (2), Hungary (3), Poland (8), Spain (3), the United Kingdom (3), and the United States (14).
- A total of 293 participants signed consent and 229 were randomized, compared with approximately 225 participants planned for randomization.
- Enrollment was geographically balanced between North America/Western Europe (53.1%) and Eastern Europe (46.9%).
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
Sponsor Vera Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to Severe Symptom State
Sponsor Horizon Therapeutics Ireland Designated Activity Company
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor Aura Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria
Sponsor Moderna Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- One participant signed informed consent but did not receive investigational product and was screen failed.
- No treatment-emergent safety or efficacy data were generated or collected.
These findings describe the trial, not the service provider’s performance or responsibility.
A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis, followed by an open label extension phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Sponsor Argenx
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- Recruitment began on 1 March 2022, and 98 participants were randomized at 57 sites in 19 countries.
- A May 2022 amendment changed the primary endpoint from complete remission on minimal OCS to CRoff at week 36 and added CRmin and IGA-BP-off-OCS secondary endpoints.
- Infection-related eligibility criteria were tightened across amendments, including exclusion of active or chronic infections and later clinically significant active infection unresolved before baseline.
- A March 2023 amendment added exclusions for latent infection, severe renal impairment, specified safety or procedure-affecting conditions, concurrent interventional-study enrollment, inadequately treated HIV, and recent live or live-attenuated vaccination.
- Sponsor confirmation of participant eligibility was removed in the March 2023 amendment.
- The March 2023 amendment required at least 30 minutes of on-site safety monitoring after investigational-product administration, and this requirement was removed in February 2024.
- The Day 10 PK sampling requirement in Part A was clarified to require samples from at least 28 participants rather than all participants.
- All adverse events in the MedDRA Infections and Infestations system organ class were designated adverse events of special interest in the May 2022 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study.
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for PPD?
The 2026-10-09 snapshot links PPD to 1,302 distinct CTIS trials. Recorded services include Laboratory services, Clinical monitoring, Project management, Safety reporting & pharmacovigilance, among 449 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for PPD?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Neurology, Respiratory. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to PPD conducted?
The linked trials record locations in 30 countries, including Spain, Italy, Germany, France, Poland. These are trial locations, not confirmed office locations or countries where PPD delivered services.
What can this page tell me about PPD's trial experience?
Browse 1,302 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 35 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 39 recorded name variants under PPD. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- PPD
- PPD (Netherlands) B.V.
- PPD (Thermo Fisher Clinical Scientific)
- PPD (UK) Limited
- PPD BioA
- PPD Bioanalytical Laboratory
- PPD Bulgaria EOOD
- PPD Central Lab
- PPD Denmark Filial Af PPD Scandinavia AB Sverige
- PPD Development (Smolensk) LLC
- PPD Development Ireland Limited
- PPD Development L.P.
- PPD Development LP
- PPD France
- PPD Germany GmbH & Co. KG
- PPD Global Central Labs
- PPD Global Central Labs (S) Pte Ltd
- PPD Global Central Labs LLC
- PPD Global Central Labs, LLC
- PPD Global Clinical Labs
- PPD Global Limited
- PPD Global Ltd.
- PPD Hungary Research and Development Ltd.
- PPD Inc
- PPD Inc.
- PPD International Holdings LLC
- PPD Ireland
- PPD Italy S.r.l.
- PPD Laboratories
- PPD Labs
- PPD Poland Sp. z o.o.
- PPD Romania S.R.L.
- PPD Slovak Republic s.r.o.
- Pharmaceutical Product Development
- Pharmaceutical Product Development LLC
- Pharmaceutical Product Development Spain S.L.
- Ppd Inc.
- Ppd Laboratories (Suzhou) Co. Ltd.
- Ppd UK Holdings Limited